Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
Air pollution is a long-standing global problem, which is responsible for 7 million deaths each year, with 7 percent of these attributed to pneumonia. A new study highlights how air pollution affects the airways making the body susceptible to developing the pneumococcal disease.
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute's long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group
There have been repeated reports of outbreaks of “vaccine-preventable disease” or VPDs across United States over the past few years. A new research letter was published this week in the JAMA Pediatrics. It was titled, “Association of Vaccine-Preventable Disease Incidence With Proposed State Vaccine Exemption Legislation.”
Researchers have uncovered a crucial link between dietary zinc intake and protection against Streptococcus pneumoniae, the primary bacterial cause of pneumonia.
A vaccine against Streptococcus pneumoniae, a major cause of childhood illness and mortality in the developing world, sharply reduced the incidence of serious pneumococcal disease among children in a large Kenyan community after it was introduced in 2011, according to a new study from researchers at the Johns Hopkins Bloomberg School of Public Health.
If mitigating racial disparities in those who contract pneumococcal diseases, such as meningitis and pneumonia, is a top public health priority, then recommending that all adults get a pneumococcal vaccine at age 50 would likely be effective guidance, according to a University of Pittsburgh School of Medicine analysis published today in the journal Vaccine.
Pfizer Inc. announced today that its 20-Valent Pneumococcal Conjugate Vaccine candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. Pfizer expects to start Phase 3 trials in a few months.
Pneumococcus is an important cause of pneumonia, sepsis and meningitis. This bacterium commonly resides in the nasal cavity.
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.
Pfizer Inc., in partnership with Parents magazine, announced today the results of a national survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious diseases, such as measles, whooping cough and invasive pneumococcal disease, and the measures parents can take to help prevent them.
Vaccines are an important part of routine healthcare for adults, seniors and women who are pregnant.
A study presented today (6 September 2016) at this year's European Respiratory Society International Congress in London, UK shows that adults admitted to hospital during school holidays are 38% more likely to have pneumococcal community-acquired pneumonia (CAP) than those admitted during term time.
Most people recoil at the thought of ingesting E. coli. But what if the headline-grabbing bacteria could be used to fight disease?
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Scientists from the University of Leicester have for the first time created a detailed image of a toxin - called pneumolysin - associated with deadly infections such as bacterial pneumonia, meningitis and septicaemia.
The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States.
The pneumococcal vaccine recommended for young children not only prevents illness and death, but also has dramatically reduced severe antibiotic-resistant infections, suggests nationwide research being presented at IDWeek 2014.
Influenza vaccination coverage estimates show an encouraging upward trend overall, but coverage among healthy 18 to 64 year-olds has yet to top 40 percent, according to new data announced at a news conference held today by the National Foundation for Infectious Diseases.
A survey of serogroup 6 Streptococcus pneumoniae isolates from children in China has identified no antibiotic-resistant clones, leading the authors to speculate that the isolates may be under antibiotic selective pressure.
Researchers report that the incidence of Streptococcus pneumoniae infection has fallen significantly in the USA in the past decade but describe a “concerning trend” whereby the baseline health status of those with serious pneumococcal disease has worsened.